Skip to main content

Fiscal Wizard · Single-issue tearsheet

ATAI / Jun 21, 2026 Run #7405

ATAI

AtaiBeckley Inc.

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Composite verdict

F 6.8 / 100
Bearish setup · Trend Following 17 drivers · 4 gates blocking
  • Double 7s
  • MA Rejection
  • Sushi Roll
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 492nd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 7Mean-reversion Neutral 44

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

13.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Revenue Growth (YoY) 100
Return on Capital Employed 0
P/B 75
Return on Assets 0
Free Cash Flow Yield 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Double 7s, MA Rejection, Sushi Roll); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
MA Rejection 11
Double 7s 11
Rate of Change 11

Risk Gates

4 blocking 6 caution

4 guards active, 20 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ATAI.